Xin Lang Cai Jing·2025-10-10 01:39Group 1 - On October 9, Rongchang Biopharma experienced a decline of 11.47% with a trading volume of 1.329 billion yuan, and the net financing purchase was 36.94 million yuan after a financing buy of 198 million yuan and a repayment of 161 million yuan [1] - As of October 9, the total balance of margin trading for Rongchang Biopharma was 828 million yuan, which accounts for 4.91% of its circulating market value, indicating a high level compared to the past year [1] - The company had a margin balance that exceeded the 90th percentile level over the past year, indicating a high level of borrowing activity [1] Group 2 - Rongchang Biopharma, established on July 4, 2008, and listed on March 31, 2022, focuses on innovative biopharmaceuticals, particularly in antibody-drug conjugates (ADC), fusion proteins, and monoclonal antibodies [2] - The company reported a revenue of 1.098 billion yuan for the first half of 2025, representing a year-on-year growth of 48.02%, while the net profit attributable to shareholders was -450 million yuan, an increase of 42.40% year-on-year [2] - The main revenue sources for the company include 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [2] Group 3 - As of June 30, 2025, the top ten circulating shareholders of Rongchang Biopharma included new entrants such as Hong Kong Central Clearing Limited and several mutual funds, indicating increased institutional interest [3] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 9.3526 million shares, while other new shareholders include Wanjiayouxuan and Huatai-PineBridge Innovation Healthcare Mixed A [3] - Some existing shareholders, such as Penghua Medical Technology Stock A and China Bank Innovation Medical Mixed A, have reduced their holdings, reflecting a shift in institutional positions [3]